Zyprexa

Caterpillar Inc., the world's No.

1 maker of earthmoving equipment, also reports today.

Its stock rose 52 cents to $62.59.

Kerkorian Stake ``All eyes will be on earnings from the big names today,'' said Farners Esparch, an analyst at Riva y Garcia Gestion SA in Barcelona, Spain, which oversees $500 million in assets.

``We've had some disappointments, so any positive surprises will give a boost'' to shares.

She said her company is ``positive on U.S.

stocks'' in the short term.

General Motors, the largest U.S.

automaker, rose 23 cents to $24.08 in Germany.

Kerkorian bought an additional 12 million of the automaker's shares.

The purchase was announced after the close of regular trading.

The carmaker may say today before the market opens that it had a loss of 16 cents per share last quarter, compared with a profit of $1.01 a year earlier, a Thomson survey showed.

Juniper Networks Inc., the world's second-largest maker of equipment that directs Internet traffic, lost $1.86, or 8.6 percent, to $19.66.

The company said yesterday that fourth- quarter sales were $575.5 million, less than the average estimate of $579.2 million in a Thomson survey of 30 analysts.

Qualcomm Slides Qualcomm Inc.

slump...

"Lilly has been more innovative than most other companies but done worse at execution," said Barbara Ryan, an analyst at Deutsche Bank.

"There's betting on a pipeline that hasn't panned out in the past." In each of the last four years, analysts' earnings projections fell through the 12 months, according to Zacks, reflecting negative developments or sentiment.

"The company is not without controversy," said Schott.

Yet, he is willing to trust Lilly because he likes the management and the strategy.

Born in Morocco and fluent in four languages, Taurel is a favorite among analysts for his direct but personable style.

Taurel acknowledged some products' performance has been disappointing, most notably Xigris, an expensive biotech drug against sepsis which is only effective in a limited population.

"We had so many new products in a short time that maybe we didn't do the best job with each," Taurel concedes.

Taurel said he was dismayed by the slowdown in Cymbalta prescriptions but has taken steps to boost sales.

More sales people are now touting Cymbalta, and Lilly launch...

"Lilly has been more innovative than most other companies but done worse at execution," said Barbara Ryan an analyst at Deutsche Bank.

"There's betting on a pipeline that hasn't panned out in the past." In each of the last four years, analysts earnings projections fell through the 12 months, according to Zacks, reflecting negative developments or sentiment.

"The company is not without controversy," said Schott.

Yet, he is willing to trust Lilly because he likes the management and the strategy.

Born in Morocco and fluent in four languages, Taurel is a favorite among analysts for his direct but personable style.

Taurel acknowledged some products' performance has been disappointing, most notably Xigris, an expensive biotech drug against sepsis which is only effective in a limited population.

"We had so many new products in a short time that maybe we didn't do the best job with each," Taurel concedes.

Taurel said he was dismayed by the slowdown in Cymbalta prescriptions but has taken steps to boost sales.

More sales people are now touting Cymbalta and Lilly launc...